4 results about "Proinsulin" patented technology

The present application relates to the technical field of mRNA vaccine, and specifically discloses a proinsulin mRNA vaccine for protecting the function and quantity of pancreatic beta cells. The vaccine is composed of a lipid nanoparticle (LNP) and an mRNA wrapped by the LNP; the mRNA is an mRNA sequence encoding proinsulin, and all uridines in the mRNA sequence are replaced by N1-methyl pseudouridine. The mRNA vaccine of the present application realizes the dual protection of the quantity and function of pancreatic beta cells, compared with the existing intervention means which only focus on blood glucose control or immune regulation, the present application delays the occurrence process of type 1 diabetes from the root, and provides a new technical scheme and drug selection for the prevention and early intervention of type 1 diabetes.

The invention relates to a TCEP-based recombinant proinsulin inclusion body denaturation and renaturation method, according to the method, TCEP is added as a reducing agent in the denaturation and renaturation process, compared with the prior art, the yield of proinsulin denaturation and renaturation is increased, and the yield of insulin is remarkably increased. Besides, TCEP is high in reducibility, wide in applicable pH range and extremely low in toxicity, so that the production efficiency and the process stability of the recombinant insulin production process can be remarkably improved, the harm to operators and the environment is reduced, and the requirements of green chemistry and safe production are met.

The invention provides a product for treating type 2 diabetes mellitus based on a stem cell insulin gene vector. The product consists of mesenchymal stem cells modified by genetic engineering and a cell preservation solution, the genetic engineering modified mesenchymal stem cells are obtained by transducing human mesenchymal stem cells by using a recombinant lentiviral vector, and the recombinant lentiviral vector can express a fusion protein composed of three parts of human proinsulin, a linker peptide and a GLP-1 receptor agonist. According to the application, human proinsulin and a GLP-1 receptor agonist are constructed into a single fusion protein, human mesenchymal stem cells are transduced by utilizing a lentiviral vector, and then a standardized three-stage induced differentiation process is carried out, so that a cell therapy product which can intelligently respond to blood glucose changes for a long time and has stable functions is finally obtained. The defects of transient treatment effect, single secretion function and large cell product batch-to-batch difference in the prior art are fundamentally overcome.

Disclosed herein is a peptide that can be used in the therapy or prevention of Type 1 Diabetes (T1D), particularly in a patient with a DR3-DQ2 haplotype, as well as methods of diagnosing or determining treatment efficacy, methods of identifying T1D-relevant antigen drivers, and to methods of identifying subjects as being at high-risk of T1D and patients as being suitable for and / or responsive to T1D treatment.